WASHINGTON, D.C. — The National Institutes of Health announced a December‑launch programme to accelerate cancer‑vaccine development, mirroring the rapid pathway used for Covid‑19 shots, and aims to fast‑track at least three candidates into Phase 3 trials within two years.

NIH Director Dr. Lawrence Tabak said the effort, dubbed “OncoVax Accelerate,” will provide $250 million in grant funding and coordinate with the FDA’s Oncology Center of Excellence to streamline IND submissions. The agency hopes to reduce the typical 10‑year timeline to under five years for promising immunotherapies.

Clinical evidence for the lead candidates is encouraging. A Phase 2 study of a melanoma‑specific peptide vaccine enrolled 1,200 patients and reported a 68% disease‑free survival rate at 24 months, compared with 52% in the control arm. Researchers attribute the gain to a 90% seroconversion rate observed in trial participants.

The FDA has granted “breakthrough therapy” designation to two of the five vaccines slated for the fast‑track, allowing for more frequent advisory committee meetings and priority review. However, the agency cautioned that none of the candidates have received final approval and that safety data will continue to be scrutinised under existing regulatory frameworks.

Oncologists anticipate a measurable impact on patient outcomes. Dr. Maya Singh, an immunotherapy specialist at Johns Hopkins, noted that an effective cancer vaccine could lower mortality for high‑risk cancers by up to 30% over the next decade, provided it reaches the market with robust efficacy data.

Key Takeaways

• NIH commits $250 million to expedite three cancer‑vaccine candidates into Phase 3 by 2026.
• Two candidates have received FDA breakthrough therapy designation, but no final approvals yet.
• Early trials show up to 68% disease‑free survival and 90% seroconversion, suggesting strong immunogenic potential.

The programme represents the most coordinated federal push for cancer immunisation since the Covid‑19 response, and its success will hinge on meeting rigorous safety standards while delivering tangible benefits to patients across the United States.